Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) had its target price lifted by Citigroup Inc. from $154.00 to $155.00 in a research report released on Tuesday morning. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently commented on the stock. FBR & Co started coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, September 15th. They issued an underperform rating for the company. Vetr upgraded shares of Alexion Pharmaceuticals from a buy rating to a strong-buy rating and set a $146.84 target price for the company in a research report on Thursday, August 25th. Piper Jaffray Cos. restated an overweight rating and issued a $185.00 target price on shares of Alexion Pharmaceuticals in a research report on Tuesday, August 16th. Jefferies Group restated a hold rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, August 9th. Finally, Brean Capital restated a buy rating and issued a $221.00 target price on shares of Alexion Pharmaceuticals in a research report on Friday, July 29th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $178.73.

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 133.69 on Tuesday. The company’s 50 day moving average price is $131.05 and its 200 day moving average price is $135.80. The firm has a market capitalization of $29.98 billion, a P/E ratio of 335.90 and a beta of 1.08. Alexion Pharmaceuticals has a 12 month low of $110.56 and a 12 month high of $193.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. The business had revenue of $753 million for the quarter, compared to the consensus estimate of $743.18 million. During the same period in the prior year, the company earned $1.44 EPS. Alexion Pharmaceuticals’s quarterly revenue was up 18.4% on a year-over-year basis. Analysts anticipate that Alexion Pharmaceuticals will post $4.65 EPS for the current year.

In related news, CEO David Hallal sold 332 shares of the firm’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $137.14, for a total value of $45,530.48. Following the transaction, the chief executive officer now directly owns 189,266 shares in the company, valued at approximately $25,955,939.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Leonard Bell sold 1,010 shares of the firm’s stock in a transaction on Monday, August 8th. The shares were sold at an average price of $137.14, for a total transaction of $138,511.40. Following the completion of the transaction, the director now owns 405,289 shares in the company, valued at $55,581,333.46. The disclosure for this sale can be found here. Insiders own 4.41% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ALXN. Legal & General Group Plc raised its position in Alexion Pharmaceuticals by 4.0% in the first quarter. Legal & General Group Plc now owns 920,520 shares of the biopharmaceutical company’s stock worth $128,153,000 after buying an additional 35,267 shares during the last quarter. Gateway Investment Advisers LLC raised its position in Alexion Pharmaceuticals by 14.2% in the second quarter. Gateway Investment Advisers LLC now owns 184,840 shares of the biopharmaceutical company’s stock worth $21,582,000 after buying an additional 23,032 shares during the last quarter. Strs Ohio raised its position in Alexion Pharmaceuticals by 10.4% in the second quarter. Strs Ohio now owns 560,109 shares of the biopharmaceutical company’s stock worth $65,398,000 after buying an additional 52,710 shares during the last quarter. Brown Advisory Inc. raised its position in Alexion Pharmaceuticals by 23.6% in the second quarter. Brown Advisory Inc. now owns 3,047,631 shares of the biopharmaceutical company’s stock worth $355,841,000 after buying an additional 581,703 shares during the last quarter. Finally, OLD National Bancorp IN raised its position in Alexion Pharmaceuticals by 12.2% in the first quarter. OLD National Bancorp IN now owns 8,204 shares of the biopharmaceutical company’s stock worth $1,142,000 after buying an additional 891 shares during the last quarter. Institutional investors and hedge funds own 96.34% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.